Orgenesis Inc. (NasdaqCM:ORGS) agreed to acquire remaining 50% stake in Theracell Laboratories SA. from Theracell Advanced Biotechnology Ltd for $13 million on July 12, 2024.Pursuant to the Purchase Agreement, in consideration for the purchase of the Assets, the Company will pay Theracell an aggregate purchase price of $13 million, which is equal to the value of the Assets established by a third-party valuation firm selected by the Company, less a debt adjustment in the amount of $10.324 million which is owed by Theracell to the Company. The aggregate Consideration will be paid by the Company as follows: $0.4 million will be paid to Theracell within 60 days after signing of the Purchase Agreement, (ii) $0.25 million will be paid to Theracell within one year after signing of the Purchase Agreement, and (iii) the remaining amount will be paid to Theracell in four equal annual payments beginning on December 30, 2025 and ending on December 30, 2028.Upon completion, Orgenesis Inc. will own 100% stake in Theracell Laboratories SA.